AUTHOR=Zhao Qiuling , He Yimin , Nian Zilin , Huang Yongjian , Huang Ruyi , Lai Lijun , Yang Lin 

TITLE=Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1404389

DOI=10.3389/fphar.2025.1404389

ISSN=1663-9812